Histamine and tryptase modulate asthmatic airway smooth muscle GM-CSF and RANTES release.
Degranulating mast cells are increased in the airway smooth muscle (ASM) of asthmatics, where they may influence ASM function. The aim of the present study was to determine whether histamine and tryptase modulate ASM cell granulocyte-macrophage colony-stimulating factor (GM-CSF) and RANTES (regulated on activation, normal T-cell expressed and secreted) release and also to examine which receptors are involved in this release. Confluent, quiescent ASM cells from asthmatic and nonasthmatic donors were treated with histamine (1 microM-100 microM) with and without histamine receptor antagonist pre-treatment, or the protease-activated receptor (PAR)-2 agonists tryptase (0.5-5 nM) and SLIGKV (100 and 400 microM). The cells were then stimulated with interleukin (IL)-1beta and/or tumour necrosis factor (TNF)-alpha (10 ng.mL(-1)) or left unstimulated for 24 h. Release of GM-CSF and RANTES was determined by ELISA and prostaglandin (PG)E(2) measured by enzyme immunoassay. Neither histamine nor tryptase induced ASM GM-CSF or RANTES secretion. However, histamine increased IL-1beta-induced GM-CSF release and markedly reduced TNF-alpha-induced RANTES release by both asthmatic and nonasthmatic cells to a similar extent, but did not modulate PGE(2) release. All changes involved activation of the histamine H1 receptor as they were partially or fully blocked by chlorpheniramine, but not ranitidine. Tryptase, via its proteolytic activity, also potentiated GM-CSF, but not RANTES, release from asthmatic and nonasthmatic ASM cells induced by both cytokines. PAR-2 involvement in the tryptase potentiation was unlikely because SLIGKV had no effect. In conclusion, mast cells, through histamine and tryptase, may locally modulate airway smooth muscle-induced inflammation in asthma.
Chhabra
J
J
Respiratory Research Group, Faculty of Pharmacy A15, University of Sydney, Sydney NSW 2006, Australia.
Li
Y-Z
YZ
Alkhouri
H
H
Blake
A E
AE
Ge
Q
Q
Armour
C L
CL
Hughes
J M
JM
D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000276:immunology* / Q000503:physiopathology*; D001980:Bronchi / Q000276:immunology* / Q000503:physiopathology*; D002478:Cells, Cultured; D018946:Chemokine CCL5 / Q000378:metabolism*; D002744:Chlorpheniramine / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism*; D006632:Histamine / Q000276:immunology / Q000494:pharmacology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D008297:Male; D008407:Mast Cells / Q000276:immunology* / Q000378:metabolism*; D008875:Middle Aged; D009130:Muscle, Smooth / Q000276:immunology* / Q000503:physiopathology*; D011899:Ranitidine / Q000494:pharmacology; D053802:Tryptases / Q000276:immunology / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D018946:Chemokine CCL5; D006634:Histamine H1 Antagonists; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D002744:Chlorpheniramine; D006632:Histamine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D011899:Ranitidine; D053802:Tryptases; D015232:Dinoprostone